Viemed Healthcare Gestione

Gestione criteri di controllo 2/4

Viemed Healthcare Il CEO è Casey Hoyt, nominato in Dec2017, e ha un mandato di 6.92 anni. la retribuzione annua totale è $ 2.51M, composta da 20.3% di stipendio e 79.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 5.59% delle azioni della società, per un valore di € 17.14M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.9 anni e 6.9 anni.

Informazioni chiave

Casey Hoyt

Amministratore delegato

US$2.5m

Compenso totale

Percentuale dello stipendio del CEO	20.3%
Mandato del CEO	6.9yrs
Proprietà del CEO	5.6%
Durata media del management	6.9yrs
Durata media del Consiglio di amministrazione	6.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Casey Hoyt rispetto agli utili di Viemed Healthcare?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	US$9m
Mar 31 2024	n/a	n/a	US$10m
Dec 31 2023	US$3m	US$509k	US$10m
Sep 30 2023	n/a	n/a	US$9m
Jun 30 2023	n/a	n/a	US$7m
Mar 31 2023	n/a	n/a	US$6m
Dec 31 2022	US$2m	US$470k	US$6m
Sep 30 2022	n/a	n/a	US$8m
Jun 30 2022	n/a	n/a	US$9m
Mar 31 2022	n/a	n/a	US$9m
Dec 31 2021	US$2m	US$470k	US$9m
Sep 30 2021	n/a	n/a	US$10m
Jun 30 2021	n/a	n/a	US$11m
Mar 31 2021	n/a	n/a	US$29m
Dec 31 2020	US$2m	US$441k	US$32m
Sep 30 2020	n/a	n/a	US$29m
Jun 30 2020	n/a	n/a	US$29m
Mar 31 2020	n/a	n/a	US$11m
Dec 31 2019	US$2m	US$425k	US$9m
Sep 30 2019	n/a	n/a	US$9m
Jun 30 2019	n/a	n/a	US$8m
Mar 31 2019	n/a	n/a	US$9m
Dec 31 2018	US$2m	US$389k	US$10m
Sep 30 2018	n/a	n/a	US$7m
Jun 30 2018	n/a	n/a	US$9m
Mar 31 2018	n/a	n/a	US$8m
Dec 31 2017	US$1m	US$235k	US$8m

Compensazione vs Mercato: La retribuzione totale di Casey ($USD 2.51M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 1.08M ).

Compensazione vs guadagni: La retribuzione di Casey è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Casey Hoyt (47 yo)

6.9yrs

Mandato

US$2,512,214

Compensazione

Mr. Casey Hoyt has been Director of Viemed Healthcare, Inc. since December 14, 2016 and Chief Executive Officer since December 2017. Mr. Hoyt served as Chief Executive Officer of Patient Home Monitoring Co...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Casey Hoyt	CEO & Director	6.9yrs	US$2.51m	5.59% € 17.1m
Michael Moore	President	6.9yrs	US$1.95m	4.76% € 14.6m
Trae Fitzgerald	Chief Financial Officer	6.9yrs	US$826.39k	0.17% € 524.1k
William Zehnder	COO & Director	6.9yrs	US$1.94m	0.58% € 1.8m
Jerome Cambre	Vice President of Sales	6.7yrs	US$805.30k	0.19% € 587.5k
William Frazier	Chief Medical Officer & Director	6.9yrs	US$328.08k	0.17% € 535.0k
Jeremy Trahan	EVP, Chief Legal Officer & Corporate Secretary	2.3yrs	Nessun dato	0.029% € 87.5k
Michael Freeman	Chief Business Development Officer	2.3yrs	Nessun dato	Nessun dato

6.9yrs

Durata media

49yo

Età media

Gestione esperta: Il team dirigenziale di VIJ è esperto e expertise (durata media dell'incarico 6.9 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Casey Hoyt	CEO & Director	7.9yrs	US$2.51m	5.59% € 17.1m
William Zehnder	COO & Director	6.9yrs	US$1.94m	0.58% € 1.8m
William Frazier	Chief Medical Officer & Director	6.9yrs	US$328.08k	0.17% € 535.0k
Randolph Dobbs	Independent Chairman	6.9yrs	US$221.63k	0.28% € 849.8k
Nitin Kaushal	Independent Director	6.9yrs	US$202.00k	0.33% € 1.0m
Sabrina Heltz	Independent Director	4yrs	US$191.00k	0.13% € 408.4k
Timothy Smokoff	Independent Director	6.9yrs	US$204.00k	0.24% € 723.1k
Bruce Greenstein	Independent Director	6.3yrs	US$199.63k	0.20% € 604.8k

6.9yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di VIJ sono considerati esperti (durata media dell'incarico 6.9 anni).

Viemed Healthcare Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Viemed Healthcare, Inc., Annual General Meeting, Jun 06, 2024

Insufficient new directors

Viemed Announces Management Appointments

Insufficient new directors

Viemed Healthcare, Inc., Annual General Meeting, Jun 09, 2022

Viemed Healthcare, Inc. Appoints Sabrina Heltz to the Board and to Serve on the Corporate Governance and Nominating Committee, the Audit Committee and the Compensation Committee of the Board

Recent updates

Viemed Healthcare, Inc. Provides Revenue Guidance for the Third Quarter of 2024

Viemed Healthcare, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Viemed Healthcare, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2024

First quarter 2024 earnings released: EPS: US$0.041 (vs US$0.04 in 1Q 2023)

Viemed Healthcare, Inc., Annual General Meeting, Jun 06, 2024

Investor sentiment deteriorates as stock falls 15%

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: US$0.27 (vs US$0.16 in FY 2022)

Viemed Healthcare, Inc. Provides Earnings Guidance for the First Quarter of 2024

Third quarter 2023 earnings released: EPS: US$0.076 (vs US$0.028 in 3Q 2022)

Investor sentiment deteriorates as stock falls 15%

Viemed Healthcare, Inc. Provides Revenue Guidance for Third Quarter of 2023

Second quarter 2023 earnings released: EPS: US$0.061 (vs US$0.025 in 2Q 2022)

First quarter 2023 earnings released: EPS: US$0.04 (vs US$0.044 in 1Q 2022)

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2023

Investor sentiment improves as stock rises 17%

Full year 2022 earnings released: EPS: US$0.16 (vs US$0.23 in FY 2021)

Investor sentiment improves as stock rises 15%

Viemed Healthcare, Inc. Wins Complete Overruling of Appealed Office of Inspector General Claims Resolving Multiyear Process with HHS and CMS

Insufficient new directors

Viemed Healthcare, Inc. Provides Revenue Guidance for the Year 2022

Third quarter 2022 earnings released: EPS: US$0.028 (vs US$0.045 in 3Q 2021)

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: US$0.025 (vs US$0.04 in 2Q 2021)

Viemed Healthcare, Inc. Announces Earnings Guidance for the Third Quarter of 2022

Viemed Announces Management Appointments

Investor sentiment improved over the past week

Viemed Healthcare, Inc. Announces Publication of Peer-Reviewed NIVH Study Finding Treatment Reduces Healthcare Costs and Saves Lives

Viemed Healthcare, Inc.(NasdaqCM:VMD) dropped from Russell 2000 Dynamic Index

First quarter 2022 earnings released: EPS: US$0.044 (vs US$0.043 in 1Q 2021)

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2022

Insufficient new directors

Viemed Healthcare, Inc., Annual General Meeting, Jun 09, 2022

Investor sentiment improved over the past week

Viemed Healthcare, Inc. Provides Revenue Guidance for the First Quarter of 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS US$0.045 (vs US$0.072 in 3Q 2020)

Viemed Healthcare, Inc. Provides Earnings Guidance for the Third Quarter of 2021

Second quarter 2021 earnings released: EPS US$0.04 (vs US$0.50 in 2Q 2020)

First quarter 2021 earnings released: EPS US$0.043 (vs US$0.11 in 1Q 2020)

Viemed Healthcare, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal 2021

Full year 2020 earnings released: EPS US$0.81 (vs US$0.23 in FY 2019)

Revenue misses expectations

New 90-day high: €8.80

Commonwealth Primary Care ACO and Viemed Healthcare Announce an Innovative Chronic Respiratory Care and Sleep Management Alliance

New 90-day high: €8.25

Investor sentiment improved over the past week

Viemed Healthcare Announces Recent Publication of Non-Invasive Ventilation Study

Viemed Healthcare, Inc. (TSX:VMD) acquired 5% stake in VeruStat, Inc for approximately $0.6 million.

New 90-day low: €6.65

Viemed Healthcare, Inc. Appoints Sabrina Heltz to the Board and to Serve on the Corporate Governance and Nominating Committee, the Audit Committee and the Compensation Committee of the Board

Revenue beats expectations

Third quarter 2020 earnings released: EPS US$0.072

New 90-day low: €6.75

New 90-day low - €7.45

First half earnings released

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media